Navigation Links
Coherent, Inc. Reports Strong First Fiscal Quarter Results and Raises Annual Sales Guidance
Date:1/28/2010

an class="xn-money">$1,063, income of $1,435 and expense of $6,798, respectively.

(F) The quarter ended October 3, 2009 includes a $1,111 ($0.05 per share) increase in valuation allowances against deferred tax assets.  

Summarized balance sheet information is as follows (unaudited, in thousands):  

    
    
    
    
                                                      January 2, October 3,
                                                         2010       2009
                                                     ----------- ----------
                             ASSETS
    Current assets:
      Cash, cash equivalents and short-term
       investments                                    $240,626    $243,635
      Accounts receivable, net                          76,136      74,235
      Inventories                                       98,924      97,767
      Prepaid expenses and other assets                 70,775      67,133
                                                        ------      ------
        Total current assets                           486,461     482,770
    Property and equipment, net                        100,062      98,792
    Other assets                                       184,182     172,042
                                                       -------     -------
        Total assets                                  $770,705    $753,604
                                                      ========    ========
    
              LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
      Current portion of long-term obligations             $21          $9
      Accounts payable                                  24,359      21,639
      Other current liabilities                         73,528      64,694
              
'/>"/>
SOURCE Coherent, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Coherent, Inc. to Webcast Third Fiscal Quarter 2008 Results
2. Coherent, Inc. Announces Termination of SEC Informal Inquiry
3. Coherent, Inc. to Webcast Fourth Fiscal Quarter 2007 Results
4. Coherent, Inc. Receives Expected Letter from NASDAQ
5. Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Medicago reports positive Phase I results for its avian flu pandemic vaccine
8. Neogen Reports 18% Increase in Net Income
9. EntreMed Reports Receipt of Third Quarter Royalty Payment
10. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... VANCOUVER, June 6 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... completed its review of QLT,USA, Inc.,s labeling supplement ... (G6PD) screening and blood monitoring,requirements., "We are ... remove,the need for blood monitoring from the Aczone ...
... Based on Increased 5-Year Survival Data for Responding ... Genta,Incorporated (OTC Bulletin Board: GNTA) announced that the ... Drug Administration (FDA) for its,New Drug Application (NDA) ... with relapsed or refractory chronic,lymphocytic leukemia (CLL). The ...
... from AHIMA, CHICAGO, June 5 "AHIMA,s Board ... promises to strengthen the effort,to address health IT from ... for senior executives. In addressing the need to,realize real ... critical,leadership challenge. AHIMA will continue working to support the ...
Cached Biology Technology:QLT announces positive Health Canada decision on Aczone(R) 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4
(Date:7/9/2014)... Atlas (TCGA) Research Network have identified novel mutations ... the most common subtype of lung cancer. Knowledge ... of possible therapeutic targets for this disease and ... treatable mutations because many potent cancer drugs that ... jointly funded and managed by the National Cancer ...
(Date:7/9/2014)... that can attack soybean crops, why would charcoal rot ... University of Illinois scientists cite the earth,s changing climate ... the fungus that causes charcoal rot. , Fungi may ... Macrophomina phaseolina , the fungus that causes charcoal ... the climate continues to change and we see more ...
(Date:7/9/2014)... with pain and fever but often can be defeated with ... and hard to beat. Now, scientists have built a new ... pyramids. Published in the journal ACS Applied Materials & ... and kill more of them than medicine alone. , David ... can lie in wait, undetectable in the human body or ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... North Hollywood, CA August 13, 2009 - The ... and support for myeloma patients, families, researchers and physicianstoday ... link between environmental toxins and bone disease in multiple ... of cells in the bone marrow that affect production ...
... the splendidly colorful leaves adorning the trees are a delight ... yellow, while the United States and East Asia boast lustrous ... differences in autumnal hues around the world? A new theory ... Education- Biology at the University of Haifa-Oranim and Prof. Jarmo ...
... deaths has declined steadily in the last three decades. ... age groups have shown some improvement, according to a ... of the American Association for Cancer Research. ... better treatment, have resulted in profound gains, but these ...
Cached Biology News:New study suggests possible genetic links between environmental toxins and multiple myeloma 2Why are autumn leaves red in America and yellow in Europe? 2Why are autumn leaves red in America and yellow in Europe? 3Cancer mortality rates experience steady decline 2
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Experion spin filters are used to filter the gel matrix and gel stain solution prior to use with the Experion automated electrophoresis system. Supplied as 10 spin filters....
Biology Products: